<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Negrin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nelson J Chao, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 19, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hematopoietic cell transplantation (HCT) is an important method for treating certain malignant and nonmalignant disorders. HCT offers potential long-term survival for patients with cancers that have a high risk for relapse, relapsed or refractory malignancies that cannot be cured using other approaches, and bone marrow failure states, including for inherited/germline conditions that affect hematopoiesis.</p><p>HCT is used to replace malignant (or defective) hematopoietic tissue using a healthy donor's hematopoietic cells. Conditioning therapy (chemotherapy and/or radiation therapy) is given to reduce the burden of disease and to prevent rejection of the donor hematopoietic cells. Hematopoiesis is then restored by infusion of a graft of healthy hematopoietic stem and progenitor cells (HSPCs) from either another individual (allogeneic HCT) or the patient's own cells (autologous HCT).</p><p>HSPCs can be obtained from peripheral blood, bone marrow, or umbilical cord blood (UCB), each of which is associated with advantages and disadvantages. Specific graft sources are preferred in certain settings, which should consider the underlying disease (ie, malignant versus nonmalignant), type of transplantation (ie, allogeneic versus autologous), recipient age, and comorbidities. The most important factor in selecting a specific donor for transplantation is immune compatibility between the recipient and donor at HLA loci. </p><p>This topic reviews the sources, preferences, and collection of HSPCs for HCT. </p><p>Selection of an HCT donor, evaluation of the donor, and the collection of UCB are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16563.html" rel="external">"Selection of an umbilical cord blood graft for hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/96033.html" rel="external">"Evaluation of the hematopoietic cell transplantation donor"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3531.html" rel="external">"Collection and storage of umbilical cord blood for hematopoietic cell transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">HEMATOPOIETIC STEM AND PROGENITOR CELLS</span><span class="headingEndMark"> — </span>HCT involves treatment with a conditioning regimen (chemotherapy and/or radiation therapy) to reduce the burden of disease, followed by an infusion of a hematopoietic graft to restore blood formation. </p><p>Successful engraftment requires infusion of sufficient hematopoietic stem cells and progenitor cells to enable hematopoietic engraftment and provide the rapid proliferation that is needed to restore blood cell formation. </p><p class="headingAnchor" id="H3726248216"><span class="h2">Description</span><span class="headingEndMark"> — </span>The hematopoietic graft must include adequate quantities of the following cell types:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematopoietic stem cells </strong>– Multipotent hematopoietic stem cells (HSCs)<strong> </strong>have the potential to develop into all blood cell lineages. </p><p></p><p class="bulletIndent1">HSCs primarily reside in bone marrow, where they comprise &lt;0.1 percent of nucleated cells. They can also be found in small numbers in the peripheral blood of adults and in umbilical cord blood (UCB). HSCs cannot be identified morphologically because they resemble small lymphocytes. As a result, they are primarily identified by immunophenotype or by their functional capacity for self-renewal. Details of the immunophenotype of HSCs are presented below. (See <a class="local">'Immunophenotype of HSPCs'</a> below.)</p><p></p><p class="bulletIndent1">HSCs are primarily quiescent. Periodically, a small percentage of HSCs emerge from this quiescent state to enter the cell cycle to proliferate. HSCs can be induced to proliferate and enter the blood stream using <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> and other approaches. (See <a class="local">'Filgrastim'</a> below.) </p><p></p><p class="bulletIndent1">Further details of HSCs are presented separately. (See  <a class="medical medical_review" href="/d/html/3536.html" rel="external">"Overview of hematopoietic stem cells"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematopoietic progenitor cells </strong>– Hematopoietic progenitor cells are progeny of HSCs that give rise to an increasingly restricted population of differentiating cells. </p><p></p><p class="bulletIndent1">Compared with HSCs, progenitor cells have a more restricted capacity to give rise to various blood cell types. There is a hierarchy of development of progenitor cells, in which they begin to commit to either the lymphoid lineages (ie, B cells, T cells, natural killer cells) or to myeloid precursors (ie, erythrocytes, platelets, neutrophils, eosinophils, basophils, monocytes, dendritic cells)  (<a class="graphic graphic_figure graphicRef52024" href="/d/graphic/52024.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1">The highly proliferative nature of progenitor cells is needed to meet the ongoing needs for blood cell replacement. It is estimated that 10<sup>10</sup> erythrocytes and 10<sup>8</sup> to 10<sup>9</sup> leukocytes are produced per hour in the steady state. Because cell numbers are maintained within narrow limits, production of blood cells can be greatly amplified on demand. </p><p></p><p>HSCs were first defined functionally as populations of cells that could rescue hematopoiesis in lethally irradiated animals. Landmark experiments showed that hematopoiesis could be restored in lethally irradiated mice by shielding the spleen with lead or by infusion of splenocytes from a normal donor [<a href="#rid1">1</a>]. Stem cells could be reisolated from these animals and used to rescue other lethally irradiated animals. </p><p>Development of in vitro and in vivo assay systems proved that clonotypic precursor cells were capable of giving rise to both erythroid and myeloid lineages of cells [<a href="#rid2">2,3</a>]. Such experiments enabled recognition of populations of cells that were functionally capable of multilineage repopulation. </p><p>Identification and isolation of HSPCs became possible with the development of monoclonal antibodies and advanced cell sorting technologies. Monoclonal antibodies were developed that could recognize proteins on the surface of immature and maturing populations of bone marrow-derived cells. Fluorescence activated cell sorting (FACS) made it possible to isolate populations of cells with properties of HSCs. Using these techniques, intravenous injection of a small population (eg, &lt;100 cells) of highly purified murine HSCs were shown to rescue &gt;95 percent of lethally irradiated animals [<a href="#rid4">4</a>]. Highly purified populations of HSPCs were shown to be capable of rapid and sustained hematopoietic engraftment in clinical trials [<a href="#rid5">5</a>]. </p><p class="headingAnchor" id="H2354529565"><span class="h2">Immunophenotype of HSPCs</span><span class="headingEndMark"> — </span>Human HSCs generally express CD34 and lack antigens associated with mature hematopoietic lineages (lineage [Lin]-negative). (See  <a class="medical medical_review" href="/d/html/3536.html" rel="external">"Overview of hematopoietic stem cells"</a>.)</p><p>Clinical trials using highly purified populations of CD34+ cells are capable of rapid and sustained hematopoietic engraftment [<a href="#rid5">5</a>]. Using magnetic bead separation, it is possible to efficiently isolate and purify CD34+ cells that can reconstitute hematopoiesis following HCT conditioning therapy. Further purification of subpopulations of CD34+ cells is possible but is challenging to perform on a clinical scale. </p><p class="headingAnchor" id="H222575116"><span class="h1">PREFERRED GRAFT SOURCES</span><span class="headingEndMark"> — </span>HSPCs for HCT can be obtained from peripheral blood, bone marrow, or umbilical cord blood (UCB). Each type of graft source has advantages and disadvantages, and no one source has been proven to be superior to another. </p><p>The preferred graft source for an individual transplant recipient is informed by the type of HCT (ie, allogeneic versus autologous), underlying disease (ie, malignant versus nonmalignant), and patient age. The most common graft source for HCT is peripheral blood, but bone marrow grafts are preferred in certain settings. UCB is an option when a histocompatible donor is not identified from related or unrelated donors. </p><p>Our approach to the selection of a graft source is similar to that of American Society for Blood and Marrow Transplantation, EBMT (formerly known as the European Society for Blood and Marrow Transplantation), and the United States National Cancer Center Network [<a href="#rid6">6-9</a>].</p><p class="headingAnchor" id="H4248131363"><span class="h2">Allogeneic HCT for malignancies</span><span class="headingEndMark"> — </span>For allogeneic HCT to treat a cancer, the preferred graft source is guided by the transplant recipient's age.</p><p class="headingAnchor" id="H697515021"><span class="h3">Adults</span><span class="headingEndMark"> — </span>For adults undergoing allogeneic HCT for a malignancy, we suggest peripheral blood grafts rather than bone marrow grafts.</p><p>Compared with bone marrow, peripheral blood grafts for adults undergoing allogeneic HCT for a cancer are associated with comparable or better survival and fewer relapses but more chronic graft-versus-host disease (GVHD). Peripheral blood grafts generally provide a greater yield of HSPCs, and the donor avoids pain and general anesthesia associated with bone marrow grafts. In highly selected patients, such as when chronic GVHD must be minimized, bone marrow is an acceptable graft source. </p><p>HSPC mobilization and collection of peripheral blood grafts are discussed below. (See <a class="local">'Peripheral blood grafts'</a> below.)</p><p>Studies that compared graft sources for adults undergoing allogeneic transplantation for cancer include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meta-analyses</strong> – Meta-analyses indicate that peripheral blood grafts are associated with equivalent or superior survival, better engraftment, fewer relapses, and better quality of life but more chronic GVHD. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A Cochrane meta-analysis that compared graft sources in HCT for adults with hematologic malignancies (1521 patients in nine randomized trials; 1994 to 2009) reported that peripheral blood and bone marrow grafts were associated with similar overall survival (OS), disease-free survival (DFS), and transplant-related mortality (TRM), but peripheral blood grafts were associated with a higher risk for extensive chronic GVHD and trends toward more acute GVHD, faster engraftment, and lower rates of relapse [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A meta-analysis of myeloablative allogeneic HCT using matched sibling donor (MSD) grafts (1111 adults in nine randomized trials; 1990 to 2002) reported that for adults who were transplanted for leukemia, peripheral blood grafts were associated with superior engraftment, fewer relapses, and a higher risk for extensive chronic GVHD; there were trends toward better OS and DFS [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Markov analysis of HCT in adults reported that peripheral blood grafts were associated with longer overall life expectancy and quality-adjusted life expectancy (QALE) compared with bone marrow grafts [<a href="#rid12">12</a>]. There was an advantage of seven months for both life expectancy and QALE with peripheral blood grafts for all conditions in which the one-year risk probability of relapse was ≥5 percent. The advantage was reversed when the risk of relapse was lower (ie, primarily nonmalignant disorders).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Individual studies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Related donors</strong> – Randomized trials that compared graft sources using human leukocyte antigen (HLA)-MSD grafts for HCT in adults with malignancies report that, compared with bone marrow, peripheral blood was associated with equivalent or superior survival but more GVHD. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A phase 3 trial of 228 patients (age 19 to 64 years) who received MSD grafts for myeloid malignancies reported better survival with peripheral blood grafts [<a href="#rid13">13</a>]. Patients who received peripheral blood grafts achieved superior 30-month OS (68 versus 60 percent; hazard ratio [HR] 0.62 [95% CI 0.39-0.97]), faster engraftment of platelets and neutrophils, and similar rates of relapse, acute GVHD, and chronic GVHD.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A trial that randomly assigned the type of graft source to 329 patients with leukemia (18 to 55 years) reported that, with nine years of follow-up, the OS, leukemia-free survival (LFS), relapse rate, and late adverse effects (AEs) were similar between trial arms, but the incidence of chronic GVHD and duration of immunosuppression were greater with peripheral blood grafts [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Long-term follow-up of a phase 3 trial of 172 patients (12 to 55 years) transplanted with MSD grafts for hematologic malignancies reported no difference in OS or GVHD between peripheral blood and bone marrow grafts [<a href="#rid15">15</a>]. After 10 years, rates of OS and LFS with peripheral blood grafts (49 and 13 percent, respectively) did not differ significantly from bone marrow grafts (57 and 28 percent, respectively). More patients who received peripheral blood grafts had GVHD (73 versus 56 percent) and required immunosuppression five years after transplantation (26 versus 12 percent), but the graft sources did not differ in performance status, return to work, incidence of bronchiolitis obliterans, or hematopoietic function.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A phase 3 trial of 350 patients (18 to 55 years) undergoing allogeneic HCT for leukemia reported comparable two-year OS, DFS, relapse, and day-100 TRM between graft sources [<a href="#rid16">16</a>]. Peripheral blood was associated with more grade ≥2 acute GVHD (52 versus 39 percent, odds ratio [OR] 1.74 [95% CI 1.1-2.7]) and more chronic GVHD (67 versus 54 percent; OR 1.7 [95% CI 1.2-2.4]) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unrelated donors</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A phase 3 trial that randomly assigned 551 patients to peripheral blood versus bone marrow grafts from HLA-matched unrelated donors (MUD) reported similar two-year OS, but peripheral blood grafts were associated with faster neutrophil and platelet engraftment, lower incidence of graft failure (3 versus 9 percent), higher incidence of extensive chronic GVHD (48 versus 32 percent), and a lower percentage of patients off GVHD therapy by two years (37 versus 57 percent) [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A retrospective review of 214 recipients of MUD grafts reported no difference between graft sources for OS, TRM, or relapse, but peripheral blood grafts were associated with an increased risk for extensive chronic GVHD [<a href="#rid18">18</a>]. </p><p></p><p class="headingAnchor" id="H156740332"><span class="h3">Children</span><span class="headingEndMark"> — </span>For children undergoing HCT for a malignancy, we suggest bone marrow grafts rather than peripheral blood grafts, based on similar or better survival outcomes and less GVHD. </p><p>No randomized trials have compared graft sources for malignancies in children, but retrospective studies report that bone marrow grafts are associated with better outcomes.</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study reported that for children with leukemia (ages 8 to 20 years) who received MSD grafts, survival was superior in the 630 patients who received bone marrow grafts compared with 143 patients who received peripheral blood grafts [<a href="#rid19">19</a>]. Peripheral blood grafts were associated with increased overall mortality (relative risk [RR] 1.38 [95% CI 1.07-1.79]), TRM (RR 1.89 [95% CI 1.28-2.80]), and chronic GVHD (RR 1.85 [95% CI 1.28-2.66]). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among children and adolescents with leukemia, survival was comparable for recipients of bone marrow grafts (650 patients) versus peripheral blood grafts (222 patients) in the CIBMTR (Center for International Blood and Marrow Transplant Registry; 2000 to 2012) registry [<a href="#rid20">20</a>]. Recipients of bone marrow and peripheral blood grafts had comparable eight-year OS (47 and 42 percent, respectively) and LFS (40 percent for both groups). However, peripheral blood was associated with higher rates of late (ie, &gt;6 months) overall mortality (HR 1.3 [95% CI 1-1.7]), late TRM (HR 1.9 [95% CI 1.3-2.9]), grade ≥2 acute GVHD (HR 1.5 [95% CI 1.2-1.8]), and chronic GVHD (HR 1.9 [95% CI 1.6-2.4]). The increased AEs with peripheral blood grafts were offset by a lower risk for relapse (HR 0.8 [95% CI 0.6-1]). There was no difference in early (ie, ≤6 months) TRM, early overall mortality, or graft failure at one year (11 percent with bone marrow versus 6 percent with peripheral blood).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow grafts were associated with superior survival for children (8 to 20 years) with leukemia who received bone marrow (630 patients) versus peripheral blood grafts (143 patients) in the Internation Bone Marrow Transplant Registry (1995 to 2000) [<a href="#rid19">19</a>]. Three-year OS with bone marrow grafts was 58 percent compared with 48 percent with peripheral blood grafts after adjusting for other significant factors. Peripheral blood grafts were associated with higher RR for mortality (RR 1.4 [95% CI 1.1-1.8]), TRM (RR 1.9 [95% CI 1.3-2.8]), and treatment failure (RR 1.3 [95% CI 1-1.7]). Relapse rates were similar (33 percent with bone marrow versus 38 percent with peripheral blood). Grade ≥3 chronic GVHD at three years was higher with peripheral blood (33 versus 19 percent; RR 1.8 [95% CI 1.3-2.6]), but rates of grade ≥2 acute GVHD were similar between graft sources.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single-institution study of allogeneic transplantation in children using unrelated donor grafts reported similar outcomes between recipients of bone marrow grafts (39 patients) versus peripheral blood grafts (35 children) [<a href="#rid21">21</a>]. OS, TRM, and relapse-free survival did not differ, but relapses were more common with bone marrow grafts than peripheral blood grafts (48 versus 24 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a CIBMTR study of transplantation for pediatric chronic myeloid leukemia, peripheral blood grafts were associated with more early mortality and GVHD but better LFS and engraftment [<a href="#rid22">22</a>]. Peripheral blood was associated with more day-100 TRM (RR 1.96 [95% CI 1.26-3.05]), chronic GVHD (RR 1.72 [95% CI 1.28-2.32]), and acute GVHD (RR 1.97 [95% CI 1.42-2.72]) but better LFS (RR 1.64 [95% CI 1.19-2.27]) and day-28 neutrophil engraftment (RR 3.87 [95% CI 1.31-11.47]).</p><p></p><p>Collection of bone marrow grafts and peripheral blood grafts are discussed below. (See <a class="local">'Bone marrow grafts'</a> below and <a class="local">'Peripheral blood grafts'</a> below.)</p><p class="headingAnchor" id="H167686761"><span class="h2">Allogeneic HCT for nonmalignant disorders</span><span class="headingEndMark"> — </span>For both adults and children who are undergoing HCT for a nonmalignant disorder, we suggest bone marrow grafts rather than peripheral blood grafts. Compared with peripheral blood, bone marrow grafts are associated with comparable or better survival and less GVHD; there is no need for a graft-versus-tumor effect in nonmalignant conditions. </p><p class="bulletIndent1"><span class="glyph">●</span>A study of 692 patients with aplastic anemia transplanted with MSDs reported that bone marrow grafts were associated with better outcomes for ages ≤20 years, but there was no difference in outcomes for older patients [<a href="#rid23">23</a>]. This CIBMTR and EBMT registry study included 558 patients who received bone marrow grafts and 134 who received peripheral blood grafts. For patients ≤20 years, peripheral blood grafts were associated with increased overall mortality (RR 2.04 [95% CI 1.09-3.78]), more chronic GVHD (RR 2.82 [95% CI 1.46-5.44]), and a trend toward inferior five-year OS (73 versus 85 percent). For patients ≥21 years, there were no significant differences between graft sources in overall mortality or chronic GVHD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decision analysis concluded that for patients with a low risk for relapse (primarily acquired aplastic anemia, hemoglobinopathies, rheumatoid arthritis, inherited marrow failure syndromes), bone marrow grafts were associated with longer life expectancy and QALE than peripheral blood grafts [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H2485037848"><span class="h2">Autologous HCT</span><span class="headingEndMark"> — </span>For autologous HCT, we recommend peripheral blood grafts rather than bone marrow grafts based on superior outcomes and avoidance of the risks of bone marrow graft collection.</p><p>Virtually all transplant centers use peripheral blood grafts rather than bone marrow grafts for autologous HCT. Compared with bone marrow, peripheral blood grafts are associated with comparable or better survival, faster engraftment, and avoidance of pain and general anesthesia associated with bone marrow grafts. Unlike allogeneic HCT, GVHD is not a problem with autologous HCT because the patient's own cells are used for the graft.</p><p>Peripheral blood grafts achieved superior OS compared with bone marrow grafts in a phase 3 trial that randomly assigned graft source for autologous HCT to 105 patients with aggressive non-Hodgkin lymphoma [<a href="#rid24">24</a>]. Compared with bone marrow, recipients of peripheral blood grafts had superior four-year OS (61 versus 43 percent), but there was no difference in four-year event-free survival (37 percent in both arms). Peripheral blood grafts achieved faster engraftment and a trend toward more complete responses (72 versus 54 percent).</p><p>Other randomized trials reported that peripheral blood grafts for lymphomas achieved faster engraftment and provided advantages with supportive care, quality of life, and cost [<a href="#rid25">25-27</a>]. A matched-pair analysis using registry data reported no difference in OS or progression-free survival by graft source in patients with lymphomas but better engraftment with peripheral blood grafts [<a href="#rid28">28</a>]. </p><p>Low levels of contaminating tumor cells can be detected in some autologous peripheral blood specimens; however, there is generally a lower level of contaminating tumor cells than that with bone marrow grafts, and its clinical significance is uncertain. </p><p>Autologous HCT is used for hematologic malignancies, solid tumors, and other conditions. Indications for autologous HCT are discussed in disease-specific topics. </p><p class="headingAnchor" id="H1312749601"><span class="h1">PERIPHERAL BLOOD GRAFTS</span><span class="headingEndMark"> — </span>HSPCs circulate at extremely low levels in peripheral blood, but mobilization can increase the yield 1000-fold or more. Mobilization protocols for peripheral blood grafts vary according to the type of transplantation (allogeneic versus autologous) and among institutions. </p><p class="headingAnchor" id="H2296869420"><span class="h2">For allogeneic HCT</span></p><p class="headingAnchor" id="H4213057059"><span class="h3">Mobilization</span><span class="headingEndMark"> — </span>For mobilization of peripheral blood grafts with allogeneic HCT, we suggest <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> (granulocyte colony stimulating factor [G-CSF]; or a biosimilar) rather than filgrastim plus a CXCR4 inhibitor (eg, <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a>). This suggestion is based on adequate mobilization for most allogeneic donors using filgrastim alone, and it avoids the substantial added cost of plerixafor. </p><p>We reserve the addition of <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> to <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> for allogeneic donors who do not adequately mobilize HSPCs with filgrastim alone. (See <a class="local">'Plerixafor for inadequate collection'</a> below.)</p><p>Some institutions routinely use <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> plus <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> for peripheral blood graft collection in allogeneic HCT. (See <a class="local">'Other strategies'</a> below.) </p><p class="headingAnchor" id="H160821681"><span class="h4">Filgrastim</span><span class="headingEndMark"> — </span>Mobilization using <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> is the most common method for collecting peripheral blood HSPCs. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – We treat with <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> 10 mcg/kg subcutaneously once daily for four days prior to leukapheresis. </p><p></p><p class="bulletIndent1">The preferred protocol for <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> mobilization varies among institutions. Some centers favor twice-daily administration of filgrastim 5 mcg/kg, but there is no persuasive evidence that this provides advantages compared with once-daily filgrastim 10 mcg/kg [<a href="#rid29">29,30</a>]. Randomized trials and other studies have reported that higher doses of filgrastim or different schedules can increase the yield of HSPCs but did not reduce the number of leukapheresis sessions and were associated with greater cost and/or more adverse effects (AEs) [<a href="#rid31">31-37</a>].</p><p></p><p class="bulletIndent1">Recombinant <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> is approved by the US Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for graft mobilization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">Filgrastim</a> is safe and well-tolerated by graft donors [<a href="#rid38">38,39</a>]. The most common AEs are local skin reactions at the injection site and mild to moderate bone pain after repeated administration. </p><p></p><p class="bulletIndent1">Rare cases of splenic rupture, alveolar hemorrhage, acute respiratory distress, Sweet syndrome, and hemoptysis have been reported, as discussed separately. (See  <a class="medical medical_review" href="/d/html/96033.html" rel="external">"Evaluation of the hematopoietic cell transplantation donor", section on 'Toxicity of PBPC donation'</a>.)</p><p></p><p class="headingAnchor" id="H1026524579"><span class="h4">Alternative cytokines</span><span class="headingEndMark"> — </span>Other cytokines are acceptable for mobilizing HSPCs, but they are used much less often than <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenograstim</strong> – Lenograstim is a glycosylated G-CSF product that can be used to mobilize HSPCs. </p><p></p><p class="bulletIndent1">Lenograstim is given at a dose of 5 mcg/kg or 10 mcg/kg, alone or in combination with chemotherapy. </p><p></p><p class="bulletIndent1">A phase 3 trial reported that random assignment to lenograstim versus <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> achieved similar efficacy [<a href="#rid40">40</a>]. Other studies also reported comparable outcomes with lenograstim [<a href="#rid41">41-53</a>]. </p><p></p><p class="bulletIndent1">Lenograstim is approved by EMA and the Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) for peripheral blood HSPC mobilization. Lenograstim is not approved in the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pegfilgrastim</strong> – Pegylated recombinant G-CSF (<a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">pegfilgrastim</a>) is a longer-acting form of G-CSF. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">Pegfilgrastim</a> 6 or 12 mg subcutaneously can be given either alone or in combination with chemotherapy. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">Pegfilgrastim</a> can safely mobilize HSPCs in adults and children with less frequent dosing than <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> [<a href="#rid54">54-63</a>], but it is not commonly used for graft mobilization. Mobilization using a single dose of pegfilgrastim daily G-CSF versus daily filgrastim in 64 patients with lymphoma reported that both approaches provided comparable mobilization and collection of CD34+ cells [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">Pegfilgrastim</a> is not approved for HSPC mobilization by the FDA or the EMA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sargramostim</strong> – Granulocyte-monocyte colony stimulating factor (GM-CSF) is no longer routinely used for peripheral blood HSPC mobilization.</p><p></p><p class="bulletIndent1">Although it is safe and effective for peripheral blood HSPC mobilization, there was a shift to <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> because GM-CSF mobilization is more often associated with fever and myalgias in the donor. </p><p></p><p class="bulletIndent1">GM-CSF is approved by the FDA for mobilization of HSPCs.</p><p></p><p class="headingAnchor" id="H1932397139"><span class="h3">Graft collection</span><span class="headingEndMark"> — </span>Peripheral blood grafts are collected via leukapheresis after four days of <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> mobilization. </p><p>Most leukapheresis procedures can be performed using antecubital veins (ie, without the need for central venous access) in one or two leukapheresis sessions. However, up to four sessions may be needed for some collections. Leukapheresis in an adult, performed through the antecubital veins, can process up to 25 liters of blood in four hours, which usually yields enough HSPCs to ensure rapid engraftment. </p><p>The leukapheresis procedure is discussed separately. (See  <a class="medical medical_review" href="/d/html/96033.html" rel="external">"Evaluation of the hematopoietic cell transplantation donor", section on 'Procedure'</a>.)</p><p class="headingAnchor" id="H698048825"><span class="h3">Cell dose and infusion</span><span class="headingEndMark"> — </span>The target dose for peripheral blood allogeneic grafts is generally ≥2 to 5 x 10<sup>6</sup> CD34+ cells/kg recipient body weight. Grafts are infused as a bedside procedure with little toxicity. It takes approximately 10 days for neutrophil recovery and 10 to 12 days for platelet recovery after graft infusion. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell dose</strong> – The CD34+ cell dose for allogeneic HCT varies with the degree of histocompatibility, but precise targets are not well-defined:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Human leukocyte antigen (HLA)-matched donor<strong> </strong>– A dose of 2 to 5 x 10<sup>6</sup> CD34+ cells/kg is adequate for allogeneic HCT using a graft from an HLA-matched sibling donor (MSD) or matched unrelated donor (MUD).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Others – For HLA-mismatched or haploidentical transplantation, a dose of 10 to 20 x 10<sup>6</sup> CD34+ cells/kg is generally administered.</p><p></p><p class="bulletIndent1">There is no established minimum CD34+ cell dose. Many centers will accept 1 x 10<sup>6</sup> CD34+ cells/kg, while recognizing that this may further delay platelet recovery. </p><p></p><p class="bulletIndent1">Studies that evaluated outcomes according to peripheral blood graft doses have reported mixed results. Higher doses generally yield slightly faster platelet recovery and have a minimal effect on neutrophil recovery and may improve clinical outcomes, but some studies reported more graft-versus-host disease (GVHD). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A registry study reported outcomes for 932 patients receiving peripheral blood grafts who were enrolled in prospective studies of the National Marrow Donor Program (1999 to 2003) [<a href="#rid64">64</a>]. Compared with lower doses, &gt;4.5 x 10<sup>6</sup> CD34+ cells/kg was associated with improved three-year overall survival (OS; 39 versus 25 percent), less transplant-related mortality (TRM), more rapid engraftment, and no increase in risk for GVHD. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another registry study, among 511 recipients of peripheral blood grafts, compared with lower doses, patients who received &gt;6 x 10<sup>6</sup> CD34+ cells/kg had a lower risk for relapse, less treatment failure, and faster neutrophil and platelet engraftment [<a href="#rid65">65</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a study of 146 patients who underwent peripheral blood allogeneic HCT (1997 to 2004), the median OS was better in patients who received 4 to 8 x 10<sup>6</sup> CD34+ cells/kg compared with those who received either lower or higher doses [<a href="#rid66">66</a>]. A retrospective study of 130 patients reported that outcomes were better for patients who received 6 to 8 x 10<sup>6</sup> CD34+ cells/kg compared with those who received higher or lower doses; multivariable analysis suggested that increasing numbers of infused cells were associated with an improved OS in a continuous fashion [<a href="#rid67">67</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A single-institution study reported that engraftment, GVHD, and OS did not vary according to CD34+ dose among 101 patients (1995 to 2002) who underwent allogeneic HCT with peripheral blood grafts [<a href="#rid68">68</a>]. In a study of 181 patients who received MSD grafts, compared with lower doses, infusion of &gt;8 x 10<sup>6</sup> CD34+ cells/kg was associated with no difference in OS, rate of relapse, or engraftment, but there was increased extensive chronic GVHD [<a href="#rid69">69</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Graft infusion</strong> – Peripheral blood grafts are infused as a bedside procedure. Infusions are generally well-tolerated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administration – Peripheral blood grafts can be either fresh or cryopreserved. The graft is thawed at the bedside and infused over several minutes [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Toxicity – Graft administration is typically associated with minimal toxicity. Significant infusional AEs, such as hypotension, cardiac arrhythmias, and electrolyte disturbances, are rare. </p><p></p><p class="bulletIndent2">Infusion of cryopreserved peripheral blood products may be associated with minor AEs, such as fever, cough, nausea, vomiting, flushing, headache, and occasional bronchospasm. Most such reactions disappear rapidly following the completion of the infusion. These reactions may be related to the cryoprotectant <a class="drug drug_general" data-topicid="8898" href="/d/drug information/8898.html" rel="external">dimethyl sulfoxide</a> (DMSO) or the quantity of granulocytes or nonmononuclear cells in the leukapheresis product [<a href="#rid71">71,72</a>]. DMSO gives off an odor for one to two days after infusion. </p><p></p><p class="bulletIndent2">Plasma depletion can be performed in cases of major ABO incompatibility, but we do not routinely do this. Instead, we use significant hydration to avoid complications of the mild hemolytic transfusion reaction. </p><p></p><p class="headingAnchor" id="H1717690391"><span class="h3">Plerixafor for inadequate collection</span><span class="headingEndMark"> — </span>When <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> alone yields inadequate levels of circulating CD34+ cells or insufficient peripheral blood HSPC collection, we suggest adding <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> rather than other approaches. </p><p>Targets for levels of circulating CD34+ cells and peripheral blood HSPC collection are discussed above. (See <a class="local">'Cell dose and infusion'</a> above.)</p><p>Some centers routinely mobilize peripheral blood HSPCs using <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> plus <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a>. Other methods of mobilization for peripheral blood grafts are discussed below. (See <a class="local">'Other strategies'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">Plerixafor</a> 240 mcg/kg is given subcutaneously when ≥4 days of <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> treatment does yield adequate peripheral blood HSPC mobilization. Graft collection generally begins the following day.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">Plerixafor</a> may be repeated for up to four consecutive days until an adequate specimen is collected. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – The most common AEs are mild diarrhea, nausea, fatigue, injection site reactions, headache, arthralgias, dizziness, and vomiting.</p><p></p><p><a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">Plerixafor</a> mobilizes functional HSPCs into the circulation within hours of injection [<a href="#rid73">73-75</a>]. Plerixafor inhibits interactions between stromal-cell-derived factor 1 (SDF-1) and its receptor, CXCR4, which plays a key role in HSPC trafficking [<a href="#rid76">76,77</a>]. </p><p>The US Food and Drug Administration has approved <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> in combination with G-CSF to mobilize HSPCs for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM). </p><p class="headingAnchor" id="H3004145151"><span class="h2">For autologous HCT</span><span class="headingEndMark"> — </span>Many patients who are undergoing autologous HCT are heavily pretreated. As many as one-third of patients may have an inadequate yield of peripheral blood HSPCs using <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> alone. </p><p class="headingAnchor" id="H3896526246"><span class="h3">Risk-adapted mobilization</span><span class="headingEndMark"> — </span>For peripheral blood grafts in autologous HCT, we suggest <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> plus the risk-adapted addition of <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> rather than other approaches. This strategy treats the patient with daily filgrastim and adds plerixafor in cases where the level of circulating CD34+ cells is insufficient and/or the collection of HSPCs is inadequate. This approach places a high value on reducing the cost of HSPC mobilization for autologous HCT. </p><p>The preferred approach for HSPC mobilization in autologous HCT varies among institutions. Some centers routinely treat with <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> plus <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> and/or chemotherapy when mobilizing HSPCs. Although a phase 3 trial found that filgrastim plus plerixafor achieved higher HSPC yields than filgrastim plus placebo, this did not affect survival for patients with NHL or MM. The routine addition of plerixafor to filgrastim and other strategies for HSPC collection with autologous HCT are discussed below. (See <a class="local">'Other strategies'</a> below.)</p><p>Our approach to risk-adapted mobilization follows. Details may differ according to institutional practice and the underlying disease. </p><p class="bulletIndent1"><span class="glyph">●</span>Treat with <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> 10 mcg/kg daily by subcutaneous injection for four consecutive days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measure circulating CD34+ cells on day 4. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For &lt;10 CD34+ cells/microL on day 4, treat with <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> 240 mg in the evening and initiate leukapheresis the following day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the first day of leukapheresis (ie, day 5) yielded &lt;1.5 x 10<sup>6</sup> CD34+ cells/kg, or if the subsequent daily yield was &lt;0.5 x 10<sup>6</sup> CD34+ cells/kg/day, add <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> daily and continue leukapheresis.</p><p></p><p>A dose of ≥2 to 5 x<sup> </sup>10<sup>6</sup> CD34+ cells/kg recipient body weight is adequate for autologous HCT in most settings; this yield correlates with 10 CD34+ cells/microL on day 4 of <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> mobilization [<a href="#rid78">78-81</a>]. Note that autologous HCT for MM may apply different targets; in some patients with MM, there may be two potential rounds of autologous HCT (ie, one for consolidation therapy and another as salvage therapy for possible future relapse). Graft collection for patients with MM is discussed separately. (See  <a class="medical medical_review" href="/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'G-CSF-based stimulation'</a>.)</p><p>Failure to achieve an adequate HSPC collection with <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> alone has been reported in up to one-third of patients undergoing autologous HCT [<a href="#rid47">47,82</a>]. By contrast, the risk-adapted strategy was associated with only 1 percent failure rate and reduced the cost and number of days of collection [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H1827701831"><span class="h3">Other strategies</span><span class="headingEndMark"> — </span>The preferred method of mobilization for autologous HCT varies among institutions. </p><p>Mobilization with <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> and risk-adapted addition of <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> is discussed above. (See <a class="local">'Risk-adapted mobilization'</a> above.)</p><p>Other approaches include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Filgrastim</strong><strong> alone</strong> – <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">Filgrastim</a> alone has been reported to yield an inadequate collection in up to one-third of patients undergoing autologous HCT [<a href="#rid47">47,82</a>].</p><p></p><p class="bulletIndent1">Mobilization using <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> is discussed above. (See <a class="local">'Mobilization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Filgrastim</strong><strong> plus routine addition of </strong><strong>plerixafor</strong> – Some institutions routinely add <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> after four days of <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> when collecting peripheral blood grafts for autologous HCT.</p><p></p><p class="bulletIndent1">A phase 3 trial reported that <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> plus <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> on day 4 and continuing daily for up to four days achieved higher HSPC yields than filgrastim plus placebo in 302 patients undergoing autologous HCT for MM [<a href="#rid43">43</a>]. However, the routine addition of plerixafor did not affect long-term survival for patients with NHL or MM [<a href="#rid84">84</a>]. </p><p></p><p class="bulletIndent1">The administration of <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> is discussed above. (See <a class="local">'Plerixafor for inadequate collection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Filgrastim</strong><strong> plus </strong><strong>motixafortide</strong> – The use of the cyclic CXCR4 inhibitor, <a class="drug drug_general" data-topicid="142706" href="/d/drug information/142706.html" rel="external">motixafortide</a>, is discussed separately. (See  <a class="medical medical_review" href="/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'G-CSF-based stimulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclophosphamide</strong><strong> with or without </strong><strong>filgrastim</strong><strong> and/or </strong><strong>plerixafor</strong> – Some centers favor the use of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (or other disease-specific chemotherapy) plus <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a>, with or without <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a>, when collecting peripheral blood grafts for autologous HCT. </p><p></p><p class="bulletIndent1">Note that the use of chemotherapy mobilization is <strong>not</strong> appropriate for HSPC mobilization in allogeneic donors. (See <a class="local">'For allogeneic HCT'</a> above.)</p><p></p><p class="bulletIndent1">We generally reserve the use of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> for autologous HSPC mobilization in patients who are unable to achieve an adequate autologous collection with G-CSF and <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a>, especially if there was an inadequate response (eg, partial response) to induction chemotherapy.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">Filgrastim</a> plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> provides higher HSPC yields than filgrastim alone, but it also the delays the start of collection and carries the risk of neutropenic fever, hemorrhagic cystitis, and possible hospitalization [<a href="#rid85">85</a>]. </p><p></p><p class="bulletIndent1">In a phase 3 trial of 47 heavily pretreated patients with relapsed or refractory lymphomas, mobilization was more effective with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> 5 g/m<sup>2</sup> followed by <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> compared with filgrastim alone [<a href="#rid86">86</a>]. After a median follow-up of 21 months, OS, progression-free survival, and engraftment did not differ between the two trial arms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Filgrastim</strong><strong> plus stem cell factor </strong>– Stem cell factor (SCF; ancestim; recombinant methionyl human stem cell factor) has limited activity as a single agent for mobilizing HSPCs, but it can enhance HSPC yield with little toxicity when combined with <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> for mobilization.</p><p></p><p class="bulletIndent1">SCF is not available in the United States or Europe. </p><p></p><p class="bulletIndent1">A phase 3 trial of 203 patients undergoing autologous HCT for breast cancer reported that the addition of SCF to <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> was more effective than filgrastim alone for mobilization and reducing the number of leukaphereses, but it did not affect the rate of engraftment [<a href="#rid87">87</a>]. </p><p></p><p class="headingAnchor" id="H3059194081"><span class="h1">BONE MARROW GRAFTS</span><span class="headingEndMark"> — </span>Collection of bone marrow grafts requires general anesthesia and is associated with substantial postoperative pain. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedure</strong> – Bone marrow grafts are obtained from the posterior iliac crests under general anesthesia. Other anatomic sites (eg, anterior iliac crests) do not provide sufficient HSPCs for successful engraftment with HCT.</p><p></p><p class="bulletIndent1">Multiple aspirations (approximately 5 to 10 mL of marrow from each puncture) are performed with the goal of collecting up to 2 x 10<sup>8</sup> cells of marrow/kg of recipient body weight. This corresponds to 700 and 1500 mL of bone marrow for an adult recipient. </p><p></p><p class="bulletIndent1">Guidelines established by the National Marrow Donor Program (NMDP) limit the volume of bone marrow removed to 20 mL/kg of donor weight. Either heparin or acid-citrate-dextran-A can be used to anticoagulate bone marrow products. If the product is to be cryopreserved, red cells are washed off prior to freezing. (See  <a class="medical medical_review" href="/d/html/96033.html" rel="external">"Evaluation of the hematopoietic cell transplantation donor", section on 'Bone marrow collection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Bone marrow donors frequently experience back or hip pain, fatigue, and transient changes in peripheral blood cell counts. </p><p></p><p class="bulletIndent1">Serious complications, such as mechanical injury, complications of anesthesia, infection, and bleeding, are extremely rare, as discussed separately. (See  <a class="medical medical_review" href="/d/html/96033.html" rel="external">"Evaluation of the hematopoietic cell transplantation donor", section on 'Complications'</a>.)</p><p></p><p class="headingAnchor" id="H2341347359"><span class="h2">Bone marrow cell dose and infusion</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell dose</strong> – The dose of a bone marrow graft is generally calculated according to the number of nucleated cells/kg of recipient body weight. A dose of 2 x 10<sup>8</sup> nucleated cells/kg is considered adequate for stable long-term engraftment. </p><p></p><p class="bulletIndent1">Retrospective studies have reported better outcomes in association with CD34+ cell dose ≥3 x 10<sup>6</sup>/kg, but cell doses of as low as 1 x 10<sup>8</sup>/kg have been used. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical outcomes were associated with bone marrow graft dose in recipients of human leukocyte antigen (HLA)-matched sibling donor (MSD) grafts for leukemia (1995 to 1998) in the IBMTR (International Bone Marrow Transplant Registry) [<a href="#rid65">65</a>]. Transplant-related mortality (TRM; relative risk [RR] 0.60 [0.37–0.96]) and treatment failure (RR 0.69 [0.56–0.97]) were lower with doses above the median (3 x 10<sup>6</sup> CD34+ cells/kg) compared with lower doses. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a retrospective single-center study of 97 patients who underwent autologous HCT for lymphomas, there was an inverse correlation between the infused CD34+ cell dose and better clinical outcomes [<a href="#rid88">88</a>]. With a median follow-up of 44 months, compared with those who received doses &lt;8.2 x 10<sup>6</sup> CD34+ cells/kg, patients who received larger doses had a better overall survival (OS; not reached versus 12 months) and longer event-free survival (not reached versus five months) in multivariate analysis. Patients who received higher doses also had faster recovery of neutrophils, platelets, and lymphocytes. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other retrospective studies identified lower, better five-year OS and lower TRM in recipients of CD34+ cell doses ≥3 x 10<sup>6</sup>/kg [<a href="#rid89">89,90</a>]. In another study, hematopoietic recovery was worse when the CD34+ cell dose was &lt;1.2 x 10<sup>6</sup>/kg [<a href="#rid91">91</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infusion</strong> – Allogeneic bone marrow products are generally used fresh and infused through a central vein over several hours to reduce infusion reactions. </p><p></p><p class="bulletIndent1">These products are associated with occasional fever, but most patients tolerate the infusion like a blood transfusion. Hemolytic reactions can occur when the ABO type of a bone marrow donor is a mismatch with the recipient. Red blood cells should be depleted prior to infusion in patients with major ABO incompatibilities [<a href="#rid92">92</a>]. </p><p></p><p class="bulletIndent1">Acute hemolytic transfusion reactions are treated in standard fashion by administering fluids and diuretics. (See  <a class="medical medical_review" href="/d/html/7932.html" rel="external">"Hemolytic transfusion reactions"</a>.)</p><p></p><p class="headingAnchor" id="H580024110"><span class="h2">Mobilized bone marrow</span><span class="headingEndMark"> — </span>Filgrastim-primed bone marrow can hasten hematologic recovery in heavily pretreated patients, but this is not often used for clinical transplantation.</p><p><a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">Filgrastim</a> 10 to 16 mcg/kg subcutaneously daily for three days can be used to prime bone marrow. </p><p>There is no evidence that bone marrow priming with <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> improves outcomes in transplant recipients:</p><p class="bulletIndent1"><span class="glyph">●</span>Compared with historical controls, there was no difference in OS, graft-versus-host disease, or platelet recovery among 17 patients who received filgrastim-primed bone marrow, but neutrophil recovery was faster, and hospitalization was shorter [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Filgrastim-primed bone marrow enabled effective hematologic recovery among heavily pretreated patients with poor peripheral blood mobilization [<a href="#rid94">94,95</a>].</p><p></p><p class="headingAnchor" id="H1925073949"><span class="h1">UMBILICAL CORD BLOOD</span><span class="headingEndMark"> — </span>Umbilical cord blood (UCB) refers to the blood remaining in the umbilical cord and placenta following the birth of an infant.</p><p>Although HSPCs are abundant in UCB, many centers routinely use two separate specimens to provide an adequate dose. Cryopreserved specimens in cord blood banks are identified based on immunologic compatibility with the recipient, thawed at the bedside, and infused over several minutes. (See  <a class="medical medical_review" href="/d/html/3531.html" rel="external">"Collection and storage of umbilical cord blood for hematopoietic cell transplantation"</a>.)</p><p>The expanded donor pool, ease of procurement, lack of donor attrition, and decreased rate of graft-versus-host disease are practical advantages for UCB grafts. Limitations include an increased risk of graft failure, delayed immune reconstitution, and unavailability of the donor for additional donations (ie, donor lymphocyte infusions). Other aspects of UCB grafts for allogeneic HCT are presented separately. (See  <a class="medical medical_review" href="/d/html/16563.html" rel="external">"Selection of an umbilical cord blood graft for hematopoietic cell transplantation", section on 'Features of UCB grafts'</a>.)</p><p class="headingAnchor" id="H31"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/686.html" rel="external">"Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – In hematopoietic cell transplantation (HCT), a graft of hematopoietic stem and progenitor cells (HSPCs) is infused to restore hematopoiesis following the administration of conditioning therapy (intensive chemotherapy and/or radiation therapy). The graft can be the patient's own cells (autologous HCT), or the donor can be another individual (allogeneic HCT). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sources of HSPCs</strong> – Potential sources for HSPC grafts for HCT are peripheral blood, bone marrow, and umbilical cord blood (UCB). Peripheral blood grafts are collected by leukapheresis, while bone marrow grafts require general anesthesia. Preferred graft sources vary with transplantation technique (allogeneic versus autologous), underlying disease (malignant versus nonmalignant), and recipient age. (See <a class="local">'Preferred graft sources'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Allogeneic HCT for malignant diseases</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Adults</strong> – For adults undergoing HCT for a malignancy, we suggest a peripheral blood graft rather than a bone marrow graft (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Adults'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Child</strong> – For children undergoing HCT for a malignancy, we suggest a bone marrow graft rather than a peripheral blood graft (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Children'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonmalignant diseases</strong> – For both adults and children undergoing HCT for a nonmalignant disorder, we suggest a bone marrow graft rather than a peripheral blood graft (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Allogeneic HCT for nonmalignant disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autologous HCT</strong> – For autologous HCT, we recommend a peripheral blood graft rather than a bone marrow graft (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Autologous HCT'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral blood grafts</strong> – Peripheral blood grafts are obtained by leukapheresis after mobilization of HSPCs. Preferred mobilization techniques vary among institutions and applications.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Allogeneic HCT</strong> – For mobilization of peripheral blood grafts in allogeneic HCT, we suggest <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> rather than filgrastim plus <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'For allogeneic HCT'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Filgrastim</strong> – <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">Filgrastim</a> administration for peripheral blood mobilization in allogeneic HCT is discussed above. (See <a class="local">'Filgrastim'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Alternative cytokines</strong> – Other cytokines can be used for mobilization. (See <a class="local">'Alternative cytokines'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Inadequate yield</strong> – When <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> alone yields inadequate levels of circulating CD34+ cells or insufficient peripheral blood HSPC collection, we suggest adding <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> rather than other approaches (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Plerixafor for inadequate collection'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autologous HCT</strong> – For peripheral blood grafts in autologous HCT, we suggest <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> plus the risk-adapted addition of <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> rather than other approaches (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Details of risk-adapted strategy for HSPC collection are discussed above. (See <a class="local">'Risk-adapted mobilization'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow grafts</strong> – Collection of bone marrow grafts requires general anesthesia and is associated with substantial postoperative pain. (See <a class="local">'Bone marrow grafts'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dose</strong> – A dose of ≥2 x 10<sup>8</sup> nucleated cells/kg recipient body weight is considered adequate. (See <a class="local">'Bone marrow cell dose and infusion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mobilized bone marrow</strong> – There is no evidence that bone marrow priming with <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> improves clinical outcomes. (See <a class="local">'Mobilized bone marrow'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Umbilical cord blood</strong> – HCT using UCB grafts is discussed separately. (See  <a class="medical medical_review" href="/d/html/16563.html" rel="external">"Selection of an umbilical cord blood graft for hematopoietic cell transplantation"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">TILL JE, McCULLOCH EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961; 14:213.</a></li><li><a class="nounderline abstract_t">Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol 1995; 11:35.</a></li><li><a class="nounderline abstract_t">Lee JY, Hong SH. Hematopoietic Stem Cells and Their Roles in Tissue Regeneration. Int J Stem Cells 2020; 13:1.</a></li><li><a class="nounderline abstract_t">Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. Science 1988; 241:58.</a></li><li><a class="nounderline abstract_t">Negrin RS, Atkinson K, Leemhuis T, et al. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant 2000; 6:262.</a></li><li><a class="nounderline abstract_t">Majhail NS, Farnia SH, Carpenter PA, et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015; 21:1863.</a></li><li><a class="nounderline abstract_t">Snowden JA, Sánchez-Ortega I, Corbacioglu S, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 2022; 57:1217.</a></li><li><a class="nounderline abstract_t">Saad A, Loren A, Bolaños-Meade J, et al. NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022. J Natl Compr Canc Netw 2023; 21:108.</a></li><li><a class="nounderline abstract_t">Duong HK, Savani BN, Copelan E, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014; 20:1262.</a></li><li><a class="nounderline abstract_t">Holtick U, Albrecht M, Chemnitz JM, et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev 2014; :CD010189.</a></li><li><a class="nounderline abstract_t">Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23:5074.</a></li><li><a class="nounderline abstract_t">Pidala J, Anasetti C, Kharfan-Dabaja MA, et al. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15:1415.</a></li><li><a class="nounderline abstract_t">Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100:1525.</a></li><li><a class="nounderline abstract_t">Friedrichs B, Tichelli A, Bacigalupo A, et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010; 11:331.</a></li><li><a class="nounderline abstract_t">Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344:175.</a></li><li><a class="nounderline abstract_t">Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100:761.</a></li><li><a class="nounderline abstract_t">Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367:1487.</a></li><li><a class="nounderline abstract_t">Remberger M, Beelen DW, Fauser A, et al. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005; 105:548.</a></li><li><a class="nounderline abstract_t">Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22:4872.</a></li><li><a class="nounderline abstract_t">Keesler DA, St Martin A, Bonfim C, et al. Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia. Biol Blood Marrow Transplant 2018; 24:2487.</a></li><li><a class="nounderline abstract_t">Remberger M, Ringdén O. Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents. Transplantation 2007; 84:551.</a></li><li><a class="nounderline abstract_t">Chaudhury S, Sparapani R, Hu ZH, et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biol Blood Marrow Transplant 2016; 22:1056.</a></li><li><a class="nounderline abstract_t">Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110:1397.</a></li><li><a class="nounderline abstract_t">Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002; 20:2344.</a></li><li><a class="nounderline abstract_t">Ottinger HD, Beelen DW, Scheulen B, et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88:2775.</a></li><li><a class="nounderline abstract_t">Vellenga E, van Agthoven M, Croockewit AJ, et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol 2001; 114:319.</a></li><li><a class="nounderline abstract_t">Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347:353.</a></li><li><a class="nounderline abstract_t">Majolino I, Pearce R, Taghipour G, Goldstone AH. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 1997; 15:509.</a></li><li><a class="nounderline abstract_t">Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010; 150:647.</a></li><li><a class="nounderline abstract_t">Anderlini P, Donato M, Lauppe MJ, et al. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol 2000; 109:770.</a></li><li><a class="nounderline abstract_t">Kröger N, Renges H, Sonnenberg S, et al. Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant 2002; 29:727.</a></li><li><a class="nounderline abstract_t">Halle P, Kanold J, Rapatel C, et al. Granulocyte colony-stimulating factor alone at 20 micrograms/kg vs. 10 micrograms/kg for peripheral blood stem cell mobilization in children. Pediatr Transplant 2000; 4:285.</a></li><li><a class="nounderline abstract_t">Koenigsmann M, Jentsch-Ullrich K, Mohren M, et al. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion 2004; 44:777.</a></li><li><a class="nounderline abstract_t">Weaver CH, Birch R, Greco FA, et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998; 100:338.</a></li><li><a class="nounderline abstract_t">Lefrère F, Zohar S, Bresson JL, et al. A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. Haematologica 2006; 91:550.</a></li><li><a class="nounderline abstract_t">Carrión R, Serrano D, Gómez-Pineda A, Díez-Martín JL. A randomised study of 10 microg/kg/day (single dose) vs 2 x 5 microg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients. Bone Marrow Transplant 2003; 32:563.</a></li><li><a class="nounderline abstract_t">Kröger N, Renges H, Krüger W, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111:761.</a></li><li><a class="nounderline abstract_t">Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25:85.</a></li><li><a class="nounderline abstract_t">Rinaldi C, Savignano C, Pasca S, et al. Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors. Transfusion 2012; 52:2387.</a></li><li><a class="nounderline abstract_t">Kopf B, De Giorgi U, Vertogen B, et al. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant 2006; 38:407.</a></li><li><a class="nounderline abstract_t">Jung EH, Byun JM, Shin DY, et al. Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122). Cancer Med 2023; 12:9186.</a></li><li><a class="nounderline abstract_t">Lisenko K, Baertsch MA, Meiser R, et al. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma. Transfusion 2017; 57:2359.</a></li><li><a class="nounderline abstract_t">DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113:5720.</a></li><li><a class="nounderline abstract_t">Karanth M, Chakrabarti S, Lovell RA, et al. A randomised study comparing peripheral blood progenitor mobilisation using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone. Bone Marrow Transplant 2004; 34:399.</a></li><li><a class="nounderline abstract_t">Orciuolo E, Buda G, Marturano E, et al. Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leuk Res 2011; 35:899.</a></li><li><a class="nounderline abstract_t">Kröger N, Zeller W, Hassan HT, et al. Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Ann Hematol 1998; 76:257.</a></li><li><a class="nounderline abstract_t">Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14:1045.</a></li><li><a class="nounderline abstract_t">Lefrère F, Bernard M, Audat F, et al. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients. Leuk Lymphoma 1999; 35:501.</a></li><li><a class="nounderline abstract_t">Lee KH, Jung SK, Kim SJ, et al. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience. Vox Sang 2014; 107:407.</a></li><li><a class="nounderline abstract_t">Fischer JC, Frick M, Wassmuth R, et al. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol 2005; 130:740.</a></li><li><a class="nounderline abstract_t">Kim S, Kim HJ, Park JS, et al. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 2005; 84:742.</a></li><li><a class="nounderline abstract_t">Ataergin S, Arpaci F, Turan M, et al. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol 2008; 83:644.</a></li><li><a class="nounderline abstract_t">Ria R, Gasparre T, Mangialardi G, et al. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant 2010; 45:277.</a></li><li><a class="nounderline abstract_t">Kroschinsky F, Hölig K, Poppe-Thiede K, et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005; 90:1665.</a></li><li><a class="nounderline abstract_t">Isidori A, Tani M, Bonifazi F, et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90:225.</a></li><li><a class="nounderline abstract_t">Simona B, Cristina R, Luca N, et al. A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. Transfus Apher Sci 2010; 43:321.</a></li><li><a class="nounderline abstract_t">Steidl U, Fenk R, Bruns I, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35:33.</a></li><li><a class="nounderline abstract_t">Kroschinsky F, Hölig K, Platzbecker U, et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006; 46:1417.</a></li><li><a class="nounderline abstract_t">Nosari A, Cairoli R, Ciapanna D, et al. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. Bone Marrow Transplant 2006; 38:413.</a></li><li><a class="nounderline abstract_t">Russell N, Mesters R, Schubert J, et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008; 93:405.</a></li><li><a class="nounderline abstract_t">Tricot G, Barlogie B, Zangari M, et al. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica 2008; 93:1739.</a></li><li><a class="nounderline abstract_t">Merlin E, Zohar S, Jérôme C, et al. Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit? Bone Marrow Transplant 2009; 43:919.</a></li><li><a class="nounderline abstract_t">Willis F, Woll P, Theti D, et al. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours. Bone Marrow Transplant 2009; 43:927.</a></li><li><a class="nounderline abstract_t">Pulsipher MA, Chitphakdithai P, Logan BR, et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009; 114:2606.</a></li><li><a class="nounderline abstract_t">Ringdén O, Barrett AJ, Zhang MJ, et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 2003; 121:874.</a></li><li><a class="nounderline abstract_t">Singh AK, Savani BN, Albert PS, Barrett AJ. Efficacy of CD34+ stem cell dose in patients undergoing allogeneic peripheral blood stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant 2007; 13:339.</a></li><li><a class="nounderline abstract_t">Mehta J, Mehta J, Frankfurt O, et al. Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2009; 50:1434.</a></li><li><a class="nounderline abstract_t">Cao TM, Wong RM, Sheehan K, et al. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol 2005; 33:279.</a></li><li><a class="nounderline abstract_t">Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98:3221.</a></li><li><a class="nounderline abstract_t">Berz D, McCormack EM, Winer ES, et al. Cryopreservation of hematopoietic stem cells. Am J Hematol 2007; 82:463.</a></li><li><a class="nounderline abstract_t">Calmels B, Lemarié C, Esterni B, et al. Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. Transfusion 2007; 47:1268.</a></li><li><a class="nounderline abstract_t">Milone G, Pinto V, Mercurio S, et al. Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cell in infused suspention and on patient age (abstract). Blood 2006; 108:402b.</a></li><li><a class="nounderline abstract_t">Pelus LM, Fukuda S. Chemokine-mobilized adult stem cells; defining a better hematopoietic graft. Leukemia 2008; 22:466.</a></li><li><a class="nounderline abstract_t">Ramirez P, Rettig MP, Uy GL, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009; 114:1340.</a></li><li><a class="nounderline abstract_t">Vose JM, Ho AD, Coiffier B, et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 2009; 50:1412.</a></li><li><a class="nounderline abstract_t">Fruehauf S, Seggewiss R. It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected]. Br J Haematol 2003; 122:360.</a></li><li><a class="nounderline abstract_t">Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood 2004; 103:1580.</a></li><li><a class="nounderline abstract_t">Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010; 45:63.</a></li><li><a class="nounderline abstract_t">Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev 2014; 28:31.</a></li><li><a class="nounderline abstract_t">Piccirillo N, Vacca M, Lanti A, et al. Poor mobilizer: a retrospective study on proven and predicted incidence according to GITMO criteria. Transfus Apher Sci 2012; 47:217.</a></li><li><a class="nounderline abstract_t">Sinha S, Gastineau D, Micallef I, et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2011; 46:943.</a></li><li><a class="nounderline abstract_t">Gertz MA, Wolf RC, Micallef IN, Gastineau DA. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010; 45:1396.</a></li><li><a class="nounderline abstract_t">Micallef IN, Sinha S, Gastineau DA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2013; 19:87.</a></li><li><a class="nounderline abstract_t">Micallef IN, Stiff PJ, Nademanee AP, et al. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transplant 2018; 24:1187.</a></li><li><a class="nounderline abstract_t">Gertz MA, Kumar SK, Lacy MQ, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009; 43:619.</a></li><li><a class="nounderline abstract_t">Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98:2059.</a></li><li><a class="nounderline abstract_t">Shpall EJ, Wheeler CA, Turner SA, et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999; 93:2491.</a></li><li><a class="nounderline abstract_t">Yoon DH, Sohn BS, Jang G, et al. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Transfusion 2009; 49:1890.</a></li><li><a class="nounderline abstract_t">Bahçeci E, Read EJ, Leitman S, et al. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Br J Haematol 2000; 108:408.</a></li><li><a class="nounderline abstract_t">Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99:2726.</a></li><li><a class="nounderline abstract_t">Zubair AC, Zahrieh D, Daley H, et al. Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion 2004; 44:253.</a></li><li><a class="nounderline abstract_t">Sniecinski IJ, Oien L, Petz LD, Blume KG. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation 1988; 45:530.</a></li><li><a class="nounderline abstract_t">Isola LM, Scigliano E, Skerrett D, et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Bone Marrow Transplant 1997; 20:1033.</a></li><li><a class="nounderline abstract_t">Lemoli RM, de Vivo A, Damiani D, et al. Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. Blood 2003; 102:1595.</a></li><li><a class="nounderline abstract_t">Seshadri T, Al-Farsi K, Stakiw J, et al. G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation. Bone Marrow Transplant 2008; 42:733.</a></li></ol></div><div id="topicVersionRevision">Topic 3537 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13776896" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8689561" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The biology of hematopoietic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31887851" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hematopoietic Stem Cells and Their Roles in Tissue Regeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2898810" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Purification and characterization of mouse hematopoietic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10871151" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26256941" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35589997" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36791762" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : NCCN Guidelines®Insights: Hematopoietic Cell Transplantation, Version 3.2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24816581" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24748537" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16051954" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19822301" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12176866" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20117965" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172139" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12130483" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23075175" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Peripheral-blood stem cells versus bone marrow from unrelated donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15367429" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15520055" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30142417" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17713443" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26964698" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17475907" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981006" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8839875" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11529850" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8598700" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9053472" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20636438" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Current status of stem cell mobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10929027" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12040468" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11079268" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Granulocyte colony-stimulating factor alone at 20 micrograms/kg vs. 10 micrograms/kg for peripheral blood stem cell mobilization in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15104662" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The role of diagnosis in patients failing peripheral blood progenitor cell mobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9488624" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585020" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12953127" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A randomised study of 10 microg/kg/day (single dose) vs 2 x 5 microg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122135" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10654020" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22452363" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16951690" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36951655" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28653421" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19363221" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15273706" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A randomised study comparing peripheral blood progenitor mobilisation using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134693" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692813" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18721768" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10609787" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25130876" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16115131" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16132903" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18508321" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19584820" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16330441" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15710576" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21036667" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15531906" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16934080" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16878144" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18268285" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18728024" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19104490" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19169289" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19608747" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12786798" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17317587" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Efficacy of CD34+ stem cell dose in patients undergoing allogeneic peripheral blood stem cell transplantation after total body irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19603344" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15730851" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11719357" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17266054" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cryopreservation of hematopoietic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17581163" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cell in infused suspention and on patient age (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17972941" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Chemokine-mobilized adult stem cells; defining a better hematopoietic graft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19571319" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19603345" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Advances in mobilization for the optimization of autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12877663" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14604975" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19543330" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24476957" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Advances in stem cell mobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22784631" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Poor mobilizer: a retrospective study on proven and predicted incidence according to GITMO criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20935680" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20062089" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22922211" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29410180" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18997825" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11567990" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194427" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453991" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10691874" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11929759" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14962317" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3279575" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Immunohematologic consequences of major ABO-mismatched bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466275" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12714501" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18711349" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
